Therefore, the simultaneous abolishment of IL-6 and DKK-1 by C6 and C37 uPAR inhibitors in our encouraging preliminary results proposes these molecules as promising targeted therapy in MM and opens new perspectives on the pathogenic role of uPAR in MM and drug resistance, as uPAR inhibitors could exert both anti-inflammatory and pro-immunosurveillance activity. Here, IL6 is linked to Miyoshi myopathy.